雅各臣科研制药(02633.HK)预期中期溢利增加超过30%
格隆汇11月13日丨雅各臣科研制药(02633.HK)公布,公司预期截至2019年9月30日止6个月录得公司股东应占综合溢利同比增加超过30%。预期增长主要归因于该集团非专利药业务的稳健增长与新获授权的产品所产生的销售收益,并加上品牌药品的销售表现提升。经营杠杆效应与成本控制措施所节省的开支亦有助实现预期盈利增长。该集团赎回可换股票据及投资物业的公平值收益亦预期在较小程度上对该公司股东应占综合溢利的增长作出贡献。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.